SYN News and Press, Synthetic Biologics Inc. From 01/05/21

Are These Penny Stocks on Your Watch List Right Now? With the new year in full swing, investors are recharged and ready to find opportunities. When first searching for the “best penny stocks ” or at least the “best” for right now, there are a few things t...

Institutional Review Board has signed off Phase 1b/2a trial evaluating Synthetic Biologics' ([[SYN]] +2.0%) SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant ((HCT)) recipients. Enrollment is expected to commence in Q1 of 2021.The 36-subject study will evalu...

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol IRB Approval Signals Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients May Proceed as Planned; Enrollment Anticipated ...

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American PR Newswire ROCKVILLE, Md., Nov. 24, 2020 ROCKVILLE, Md. , Nov. 24, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage c...

Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options PR Newswire ROCKVILLE, Md., Nov. 16, 2020 ROCKVILLE, Md. , Nov. 16, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), ...

Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors -- Dr. Monahan brings extensive drug development, clinical, regulatory, commercial and licensing experience -- PR Newswire ROCKVILLE, Md., Nov. 12, 2020 ROCKVILLE, Md...

Synthetic Biologics, Inc. (SYN) Q3 2020 Earnings Conference Call November 10, 2020 04:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steven Shallcross - Chief Executive Officer & Financial Officer Michael Kaleko - Senior Vice President, Research & De...

Synthetic Biologics (SYN): Q3 GAAP EPS of -$0.14 beats by $0.03.Cash and equivalents totaled $6M, a decrease of $9M from December 31, 2019.Also, received study-may-proceed letter from the FDA supporting a Phase 1 single ascending dose study of SYN-020 IAP; Phase 1 study to support development...

Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results -- Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 ...

Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020 -- Conference Call Scheduled for Tuesday, November 10, 2020 at 4:30 p.m. ET -- PR Newswire ROCKVILLE, Md., Nov. 3, 2020 ROCKVILLE, Md. , Nov. ...